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Background: Stereotactic ablative body radiation (SABR) is a novel and sophisticated radiation modality that
involves the irradiation of extracranial tumors through precise and very high doses in patients with oligometastatic
lung disease and primary lung tumors.
Case presentation: A 52-year-old female with subclinical idiopathic interstitial lung disease (ILD) and oligometastatic
lung disease from squamous urethral cancer who was treated with SABR for a metastatic lesion located in the right
lower pulmonary lobe. The patient received a hypo-fractionated course of SABR. A 3D-conformal multifield technique
was used with six coplanar and one non-coplanar statics beams. A 48 Gy total dose in three fractions over six days was
prescribed to the 95% of the PTV. The presence of idiopathic ILD and other identifiable underlying lung conditions
were not taken into account as a constraint to prescribe a different than standard total dose or fractionation schedule.
Six months after the SABR treatment, a CT-scan showed the presence of a pneumomediastinum with air outside the
bronchial tree and within the subcutaneous tissue without co-existing pneumothorax. To our knowledge, this is the
first case of pneumomediastinum appearing 6 months after SABR treatment for a lung metastasis located in the
perihiliar/central tumors region as defined by the RTOG protocols as the proximal bronchial tree.
Conclusion: Radiation oncologist should be aware of the potential risk of severe lung toxicity caused by SABR
in patients with ILD, especially when chemotherapy-induced pulmonary toxicity is administered in a short time
interval.
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(stereotactic beam radiation therapy)Background
Stereotactic ablative body radiation (SABR) is a novel
and sophisticated radiation modality that involves the ir-
radiation of extracranial tumors using precise and very
high doses of radiation delivered in one to five fractions.
This modality has been used in the treatment of non-
metastatic primary cancer and also in the case of oligo-
metastases [1]. Phase I/II studies data from patients with
oligometastatic lung disease who were treated with SABR
or SBRT (stereotactic body radiation therapy), seem to be
very promising with high local control rates and long-
term survivors in properly selected patients [2,3].* Correspondence: mrruiz@unav.es
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article, unless otherwise stated.SABR for lung metastases can produce several lung
toxicities, such as airways collapse, atelectasis, symptom-
atic pneumonitis, fibrosis and pathological vertebral
fracture [4]. The incidence of symptomatic radiation
pneumonitis or grade 3–4 pneumonitis is low, in the
range of 0-5% [5]. The risk of pneumonitis is associ-
ated with the type of chemotherapy regimen previously
administrated, dosimetric parameters, and patient’s age.
Non-pulmonary adverse effects, such as esophagitis,
esophageal stenosis, massive hemoptysis, pleural effu-
sion and pericardial effusion have been described in
patients treated with SABR. The development of these
adverse events depend on the location of the tumor and
the dose regimen used. A phase II study conducted at Indi-
ana University observed excessive toxicities in 70 patients
with central and perihiliar lung tumors treated with high
doses of radiation delivered during SBRT (60–66 Gy inCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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tients experienced severe toxicity, including decline in pul-
monary function tests, pleural effusion, and pneumonia.
Authors informed of 6 treatment-related deaths, the major-
ity of which were due to pneumonia. Moreover, patients
with central tumors showed an 11-fold increased risk of
presenting a severe toxicity compared to patients with per-
ipheral lesions.
To our knowledge, we report the first case of pneumo-
mediastinum appearing 6 months after treatment with
SABR for a solitary lung metastasis located in the perihi-
liar/central tumors region defined by the RTOG proto-
cols as the proximal bronchial tree.
Case presentation
A 52-year-old woman with idiopathic interstitial lung
disease was referred to our department in March 2010
for a second opinion regarding a metastatic urethral car-
cinoma. Her history began one year ago when she no-
ticed a node in the urethral meatus by self-palpation
associated with perineal pain. Magnetic Resonance (MR)
images demonstrated a 2 x 1.5 cm urethral nodule with
urethral thickening including the trigone and a single
iliac lymph node of 1.2 cm of diameter. A cystoscopy
with biopsy revealed a well differentiated infiltrating epi-
dermoid urethral cancer with positive surgical margins.
Staging CT-scans were performed showing no distant
metastatic disease. On July 2010, the patient underwent
anterior pelvic exenteration, urostomy with ileal bladder
reconstruction and vaginal reconstruction with a trans-
verse rectus abdominis myocutaneous (TRAM) flap.
The disease was followed until November 2010, when
the physical examination demonstrated the presence of a
nodule of 3 cm in the right subvaginal space and bilateral
metastatic inguinal lymph nodes. The positron emission
tomography/computed tomography (PET-CT) revealed
tumor recurrence near of the neovagina, the presence of
bilateral inguinal lymph nodes and a single lung metasta-
ses. A fine-needle aspiration biopsy was obtained from in-
guinal lymph nodes and the pathologic study confirmed
lymph node metastasis of squamous-cell carcinoma of the
urethra. The patient was initially treated with six cycles of
chemotherapy using paclitaxel 175 mg/m2 on day 1, cis-
platin 75 mg/m2 on day 1 and capecitabine 750 mg/m2 on
days 1–15 every 21 days. Complete clinical response was
observed after six cycles of chemotherapy.
Between March and May 2011, a consolidation hypo-
fractionated course of IMRT (intensity-modulated radi-
ation therapy) was delivered using the step-and-shoot
technique. The IMRT dose administrated was 62 Gy pre-
scribed to the 95% of the clinical target volume (CTV =
urethra and inguino-pelvic lymph node (LN) in 25 frac-
tions, 2.48 Gy/fraction. Three cycles of chemotherapy with
paclitaxel 50 mg/m2 and Cisplatin 30 mg/m2 on a weeklyregimen were concomitantly given throughout the whole
course of IMRT. IMRT was followed by a short course of
high-dose-rate (HDR) intravaginal brachytherapy. A dose
of 4.75 Gy was prescribed at minimum target dose
(MTD), over three consecutive days with a total dose of
19 Gy.
The patient was followed until June 2011, when the
image studies confirmed a single metastatic lesion on
the right lower lung lobe as the unique location of meta-
static disease. With the diagnosis of disease progression
with a single lung metastatic lesion measuring 30 X
26 mm, a hypofractionated course of SABR was deliv-
ered to the metastatic lung tumor. She was placed in su-
pine position and was immobilized using an alpha cradle
device to improve patient position reproducibility during
daily treatments. Respiratory tumor movement was ob-
served under fluoroscopy. A planning CT scan was per-
formed with a combination of three sets of CT scans
obtained during free breathing, deep inspiration and
deep expiration to generate an internal target volume
(ITV) that accounts for respiratory motion. The gross
tumor volume (GTV) was the lung nodule, and the PTV in-
cluded the ITV with a symmetric 0.5 cm margin (Figure 1).
“Organs at risk (OARS) were delimited and constraints were
established based on recommendations used in recent
RTOG SABR trials (RTOG 0618, 0813 and 0915) and
NCCN guidelines (Figure 2). This guidelines concluded
that to minimize toxicity when treating lesions in close
proximity to the bronchial tree, the Dmax of the tra-
chea and proximal bronqui should be < 30 Gy. In this
patient, the Dmax was 12.51 Gy (10.5 cc) and 30,9 Gy
(1,69 cc), respectively”.
A 3D-conformal multi-field technique was selected with
six coplanar and one non-coplanar statics beams. SABR
was delivered by a linear accelerator (Oncor, Siemens,
Palo Alto, California, USA) with 6-MV photons. A total
dose of 48 Gy in three fractions over a six days period was
prescribed to the 95% of the PTV (Figure 3). Patient posi-
tioning and isocenter verification were checked using cone
beam CT. The patient had an excellent inmediate toler-
ance to the SABR treatment.
Results
The patient continued a regular follow-up program in-
cluding clinical history, physical examination, complete
blood count, liver and renal function tests and thoracic,
abdominal, and pelvic CT scans every 3 months. Six
months after the SABR procedure she referred cervical
pain and progressive respiratory deterioration with cough,
expectoration and dyspnea. Chest X-ray showed diffuse
reticular interstitial lesions in both lungs. The bacterio-
logical and fungal culture of blood and sputum were
negative. The chest CT scan continued to show complete
response of the metastatic lung disease with signs of
Figure 1 A combination set of three CT scans obtained during free breathing (pink), deep inspiration (yellow) and deep expiration
(blue) were used to generate an internal target volume (ITV) that accounts for respiratory motion (red). The blue dots outline the lung
structure and the red dots indicate the radiation target. Digital Reconstructed Radiography (DRR) show the trachea (blue) and bronchial tree
(yellow) structure and the targets volumenes (the lung nodule (green), and the PTV (dark blue) included the ITV (red) with a symmetric
0.5 cm margin.
Figure 2 Dose volume histograms showing dosimetric parameters analyzed including targets and organs at risk.
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Figure 3 Dose distribution in the treatment course: Radiotherapy treatment planning with high conformity. Pink, green and dark blue
and light blue areas represent 47 Gy, 45 Gy, 40 Gy and 30 Gy, respectively. The blue dots outline the lung structure and the sky-blue dots indicate
the radiation target.
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diffuse irregular interlobular thickness and little honey-
combing pattern of the right lung in accordance with her
known chronic lung fibrosis. Surprisingly, the CT scan
also illustrated a new image of a pneumomediastinum
with air outside the bronchial tree with the presence of
diffuse subcutaneous air without co-existing pneumo-
thorax. The patient was diagnosed of radiation pneumon-
itis and pneumomediastinum in an idiopathic pulmonary
fibrosis setting (Figure 4). A bronchoscopy was done to rule
out the presence of an airway leak showing no pathological
findings at the procedure. clarithromycin 500 mg/12 h, ster-
oid therapy with dexametasone 4 mg/8 h and, E-vitamin
were administered for inflammatory lung disease. Two
weeks after treatment initiation, the patient remained
clinically stabilized and radiological response of pneu-
momediastinum but a MRI of the spinal cord was per-
formed due to the appearance of moderate neck pain.
MRI showed a massive vertebral metastatic (C3) lesion
that was treated with palliative radiation therapy (35 Gy
in 14 fractions). The patient continued a regular follow-up
program and remained asymptomatic but she was diag-
nosed of multiple bilateral lung metastases in a CT scan
and multiple spinal cord metastases in MR images. A sec-
ond line of chemotherapy was initiated with carboplatin
(AUC 3) and gemcitabine 1300 mg/m2 every two weeks.Despite this treatment the patient had a progressive clin-
ical and radiological worsening and she died on November
6, 2011. The family refused autopsy.
Discussion
The development of novel and sophisticated irradiation
techniques such as SABR represents a progress in plan-
ning and delivering external beam radiotherapy. SABR
delivers large doses of radiation in few fractions, and it
has been demonstrated to be a safe, effective and prom-
ise ablative technique for the treatment of selected
patients with lung metastases. Patients diagnosed of
oligometastatic lung disease who are considered inop-
erable or patients that are not candidates for surgical
treatment, SABR emerges as a practical option. The
reported 2-year overall survival ranges from 67% to
100% and the 2-year local control rate has been estab-
lished between 92% and 95% [6].
We present the first case of SABR-induced pneumo-
mediastinum in a patient with a solitry lung metastasis
and subclinical interstitial lung disease (ILD). A total
dose of 48 Gy in three fractions over six days was ad-
ministered to the 95% of the PTV (Figures 3-4). The
PTV, which includes setup uncertainty and residual tar-
get motion was designed from the GTV by enlarging the
volume 0.5 cm in the axial plane and 1.0 cm in the
Figure 4 AP and lateral view of Chest X-ray show the presence of free air in the mediastinal cavity. Transverse Chest computed
tomography (CT) after SBRT shows ground-glass opacities, bleeds confined to the right upper lung, and diffuse ground-glass attenuation, bleeds
in the marginal areas, airspace consolidation, free air in the mediastinal cavity and fibrosis in the bilateral upper and lower lung fields. Transverse
chest CT view of radiation dose distribution in the treatment course. Pink, green and dark blue, light blue and orange areas represent 47 Gy,
45 Gy, 40 Gy, 30 Gy and 20 Gy, respectively.
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case, we discard abdominal compression to reduce re-
spiratory motion because comparing free breathing and
abdominal compression there was no differences in tumor
motion.
Radiation pneumonitis (RP) is one of the most significant
complications for patients treated with SBRT [7] and fatal
radiation toxicity has been reported in patients with
centrally-located stage I lung cancer [3]. Timmerman
et al. described six SBRT-related deaths in patients with in-
operable stage I lung cancer treated with 60–66 Gy in
three fractions during 1–2 weeks. The causes of death were
pneumonia, pericardial effusion and massive hemoptysis.Subclinical ILD was not found to be a significant fac-
tor for grade 2–5 RP or clinical outcomes in a recent
Japanese study where 100 patients with 124 lung tumors
were treated with SABR. Patients with subclinical (un-
treated and oxygen-free) ILD were treated with SABR
(48 Gy in four fractions), while those with clinical ILD
(post- or under treatment) were not. However, a signifi-
cant finding was the presence of uncommon extensive
RP in patients with subclinical ILD [8]. Our patient was
previously diagnosed of subclinical ILD and she pre-
sented pneumomediastinum confirmed by the presence
of free air in the mediastinal structures 6 months after
SBRT. Another risk factor in this patient associated with
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radiation in three fractions (16 Gy x 3) in a lesion located
in the perihiliar region. In the other hand, we think that
the presence of idiopathic ILD and other lung disease
should be taken into account as a more restrictive con-
straint trying to achieve a BED> =100 Gy. These selected
patients can be treated with 4 to 10 fractions risk-adapted
SABR regimens.
To our knowledge, pneumomediastinum has not been
associated as a complication related to SABR of a pri-
mary lung cancer or lung metastasis. Pneumomediasti-
num was described in the early 19th century by the
pathologist R. T. Läennec, who first observed this condi-
tion in trauma patients [9]. Primary or spontaneous
pneumomediastinum (SPM) is caused by increased pres-
sure gradient between the alveoli and pulmonary inter-
stitium. SPM represents approximately 1% of all cases of
pneumomediastinum (PM) and is generally a benign process
that mainly affects young people, especially male smokers
[10]. Underlying lung conditions as asthma, ILD (loss of in-
tegrity of the alveolar-capillary membrane), pneumonia, bul-
lous lung, and radiation therapy for lung cancer have all
been associated with SPM [10]. ILD has been identified as
the most frequent predisposing factor to PM [11]. Franquet
et al. [12] found SPM in 4 patients of 78 patients (5.1%) with
idiopathic pulmonary fibrosis. They assessed the presence
and distribution of pulmonary parenchymal abnormalities
on CT images at the time of detection of pneumomediasti-
num, and the author observed parenchymal abnormalities
such as ground-glass attenuation or honeycombing pattern
with a subpleural predominant distribution.
In a study of 34 patients with interstitial pulmonary fi-
brosis, Fujiwara et al. [13] identified pneumomediastinum
on chest CT scans in 5 patients (14.7%). However, they did
not assess parenchymal abnormalities at the onset of
pneumomediastinum, and assumed that honeycombing
pattern and violent cough were predisposing factors for
pneumomediastinum.
Our patient had evidence of idiopathic ILD observed
several years ago in CT images showing an irregular sep-
tal and reticular pattern located in the axial and sub-
pleural interstitium predominantly in the peripheral and
basal regions. Reviewing the treatment plan, the treated
metastatic lesion was located into the area with higher
density of interstitial pattern, the volume receiving at
least 20 Gy (V20) was 18% and the mean lung dose was
7.81 Gy (Figure 3-4). These dosimetric parameters are
considered in the literature as low risk of pneumonitis
after SBRT. To our knowledge, the spontaneous pneu-
momediastinum and pneumotorax in lung cancer fol-
lowing chemotherapy and radiotherapy may occur due
to a variety of mechanisms such as: 1) the rapid tumor
lysis and defective tissue repair leading to rupture of a
periphereal necrotic pulmonary nodule into the pleuralspace and/or the bronchus resulting in a bronchopleural
fistula and pneumotorax; or 2) the rapid formation of a
tumor cavity after radiation therapy with subsequent en-
largement and penetration into pleural space. No radi-
ation dose–response effect has been described in the
literature, although pneumothorax and pneumomediati-
num were not observed in patients who received less
than 3000 cGy [14,15]. Chemotherapy also does not ap-
pear to correlate with the occurrence of SPT. However,
SPT in patients with ILD receiving potentially pneumo-
toxic chemotherapy, such as chemotherapy-induced inter-
stitial fibrosis and pneumonia, usually SPT is severe,
bilateral, and/or recurrent [16].
In addition to ILD, our patient had other lung condi-
tions associated with PM as to have a metastatic cancer
in the lung and to receive pneumotoxic chemotherapy.
Pulmonary toxicities due to gemcitabine have been re-
ported. Dyspnea occurs in approximately 25% of patients
treated with gemcitabine, whereas serious pulmonary
toxicities are much less common, approximately 0.3% of
patients present severe pulmonary adverse effects [17].
Gemcitabine can induce radiation recall reactions [18]
and the elapsed time required for recall reaction after
gemcitabine administration range from 3 days to 8 months
[19]. Our patient developed pneumomediastinum 2 weeks
after gemcitabine administration and 6 months after SBRT
treatment and it is difficult to asses the relative input of
gemcitabine in the development of pneumomediastinum
but a probable synergistic effect between gemcitabine and
SBRT could have been responsible for this severe pulmon-
ary toxicity.
Perhaps, the presence in this patient of multiple predispos-
ing factors with the addition of a precipitating factor such as
the delivering of an ablative radiation dose have caused the
loss of integrity of the alveolar-capillary membrane and con-
sequently the development of pneumomediastinum.
Conclusions
We describe a 52-year-old female with oligometastatic
lung disease from squamous-cell urethral carcinoma who
was treated with SABR for a solitary metastatic lesion lo-
cated in the right lower pulmonary lobe. The presence of
idiopathic ILD and other identifiable underlying lung con-
ditions were not taken into account as a constraint to pre-
scribe a different total dose or fractionation schedule.
Radiation oncologist should be aware of the potential
risk of severe lung toxicity caused by SBRT in patients
with ILD, especially when pulmonary toxicity-inducible
chemotherapy is administered in a short time interval.
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